QL1101

DRUG4 trials

Sponsors

Qilu Pharmaceutical Co., Ltd., Yongpeng Wang

Conditions

Non Small Cell Lung CancerNon-squamous Non-small Cell Lung CancerOvarian CancerTumor

Phase 1

A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

CompletedNCT06232902

Qilu Pharmaceutical Co., Ltd.Tumor

Start: 2024-06-20End: 2024-11-18Updated: 2024-12-18

Phase 2

A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Yongpeng WangOvarian Cancer

Start: 2023-07-27End: 2025-12-22Target: 25Updated: 2023-07-28

Phase 3

Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer

CompletedNCT03169335

Qilu Pharmaceutical Co., Ltd.Non-squamous Non-small Cell Lung Cancer

Start: 2017-03-28End: 2018-07-13Updated: 2018-08-24

Unknown Phase

To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer

Qilu Pharmaceutical Co., Ltd.Non Small Cell Lung Cancer

Start: 2017-03-01End: 2018-12-10Target: 15Updated: 2017-06-22

Related Papers

A multi-center, randomized, double-blind, parallel, two-group phase III clinical study on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in the first-line treatment of non-squamous non-small cell lung cancer

Annals of Oncology2019-04-014 citations